

NEWSLETTER



Intoinworld Co., Ltd. is a Contract Research Organization (CRO) founded by experts with extensive experience in the clinical trial field. Our goal is to promote the growth of the clinical trial sector by fostering talented professionals.

We prioritize compliance with clinical trial regulations and principles, continually investing in and nurturing specialized personnel to provide the highest quality services.

We are here!



IntoinWorld is joining BIO KOREA 2025!

Date : May 7- 9

Vanue : Hall C COEX, Samsung Station

Booth : H 32



Where Does Korea's AI-Driven Drug Development Stand?

Quantum computing in drug development is not yet mainstream, as current technology remains imperfect. It allows targeted drug screening by selecting specific compounds, but is limited to small-scale computations. Major global pharma companies are investing heavily in quantum computing for drug discovery, with expectations of significant breakthroughs within three years.



"Soaring Up or Crashing Down"... Is It Time for Biotech Stocks?

Biotech stocks are surging, driven by limited exposure to tariff wars, anticipation of U.S. rate cuts, and the upcoming AACR conference. Advances in rare disease treatments, cancer therapies, and NK cell technology are fueling share price gains. Some companies have soared over 90% due to successful clinical trials and tech transfers. However, the risk of sharp declines from clinical failures remains significant.

INTOINWORLD



Intoinworld

Pharma Nutraceutical Affiliates See Profitability Slide: Rising Losses, Shrinking Margins

Last year, the profitability of nutraceutical affiliates under major Korean pharmaceutical companies declined significantly, with average operating margins falling sharply compared to the previous year. Instances of losses, increased deficits, and reduced profits outnumbered cases of improved performance. While some firms achieved profitability or reduced losses, none recorded high margins. Despite revenue growth, profits often shrank, underscoring a clear trend of declining profitability.



<2021~2025년 중국 미용 주사 재료 시장 규모 및 제품 점유율>

(단위: 억 원안, %)



[자료: Frost & Sullivan]

Korean "Hyaluronic Acid-Botox" Brands Lead China's Booming Aesthetic Injectables Market

Korean brands are leading China's aesthetic injectables market, excelling in materials like hyaluronic acid, Botox, collagen, and regenerative substances. In 2024, the market reached 6.7 trillion won, growing 30% annually. Korea dominates imported hyaluronic acid and tops the Botox market with cost-effective products. Recombinant collagen and regenerative injectables are viewed as blue-ocean markets with low competition and high potential. Emerging technologies like exosomes are gaining attention, boosting export opportunities for Korean innovations.

Pharma Companies Expand Beyond Pet Meds and Food, Targeting Community Engagement

Korean pharmaceutical companies are positioning the pet industry as a future growth engine, launching medications, food, and nutraceuticals while leveraging community-based marketing. Some are investing in animal drug development and pet community platforms to expand their market presence. The domestic pet market, valued at 8.5 trillion won in 2022, is expected to grow to 21 trillion won by 2032. Communities are likely to serve as key channels for product promotion and word-of-mouth marketing.

